Share This Article:

Quantification of Steroid Receptors Gene Expression in Breast Cancer Patients: Possible Correlation with Serum Level of Adipocytokines

Abstract Full-Text HTML Download Download as PDF (Size:249KB) PP. 659-665
DOI: 10.4236/jct.2011.25088    3,263 Downloads   6,583 Views   Citations


Background: While the role of adipocyte-derived hormones in breast cancer pathogenesis well studied, it is speculated that there is a crosstalk between adipocytokines and Esterogen receptor(ER) signaling. To test this hypothesis we evaluate the possible correlation between serum levels of adipocytokins with steroid hormone receptors gene expression in breast cancer patients. Methods: In this case-control study, 70 women with breast cancer participated with different grades of obesity (36 none obese, BMI < 25 kg/m2 and 34 obese, BMI ≥ 25 kg/m2). Serum level of adiponectin, leptin, TNFα and IL6 determined by ELISA. Following quantitative expression of androgen receptor (AR), progesterone receptor (PR) and estrogen receptors (ERα and ERβ) mRNA in tumor tissues evaluated by Real-time PCR. Results: We find a significant reverse correlation between serum level of Adiponectin and ERα and PR mRNA (r = –0.229, n = 64, p = 0.035 and r = –0.220, n = 64, p = 0.041) but no correlation was between adiponectin and, ERβ and AR in samples (P > 0.05). In case of leptin, we observed a positive correlation between leptin and ERα and PR mRNA. (r = 0.553, n = 64, p < 0.001, r = 0.359, n = 64, p = 0.002 and a reverse significant correlation between leptin and ERβ (r= –0.506, n = 64 and p < 0.001). We also observed a significant correlation between TNFα and IL6 with steroid receptors gene expression in samples (P < 0.05). Conclusion: As the presence of steroid receptors are used as the most common prognostic markers in breast cancer patients, so targeting adipocytokines as potential regulators of steroid receptorsgene expression can be a new approach in treatment of obese breast cancer subjects.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

R. Esfahlan, N. Zarghami, Μ. Rahmati-Yamchi, A. Monfaredan, S. Valiyari, A. Esfahlan, R. Jozani, M. Gojazadeh, F. Mamaghani and M. Mobasseri, "Quantification of Steroid Receptors Gene Expression in Breast Cancer Patients: Possible Correlation with Serum Level of Adipocytokines," Journal of Cancer Therapy, Vol. 2 No. 5, 2011, pp. 659-665. doi: 10.4236/jct.2011.25088.


[1] D. Housa, J. Housova, Z. Vernerova and M. Haluzik, “Adipocytokines and Cancer,” Physiological Research, Vol. 55, No. 3, 2006, pp. 233-244.
[2] A. R. Carmichael, S. Bendall, L. Lockerbie, R. J. Prescott and T. Bates, “Does Obesity Compromise Survival in Women with Breast Cancer?” Breast, Vol. 13, No. 2, 2004, pp. 93-96. doi:10.1016/j.breast.2003.03.002
[3] S. Loi, R. L. Milne, M. L. Friedlander, M. R. McCredie, G. G. Giles, J. L. Hopper and K. A. Phillips, “Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer,” Cancer Epidemiology, Biomarkers and Prevention, Vol. 14, No. 7, 2005, pp. 1686-1691. doi:10.1158/1055-9965.EPI-05-0042
[4] A. R. Carmichael and T. Bates, “Obesity and Breast Cancer: A Review of the Literature,” Breast, Vol. 13, No. 2, 2004, pp. 85-92. doi:10.1016/j.breast.2003.03.001
[5] A. R. Carmichael, “Obesity as a Risk Factor for Development and Poor Prognosis of Breast Cancer,” An International Journal of Obstetrics and Gynaecology, Vol. 113, No. 10, 2006, pp. 1160-1166. doi:10.1111/j.1471-0528.2006.01021.x
[6] V. Speirs and R. A. Walker, “New Perspectives into the Biological and Clinical Relevance of Oestrogen Receptors in the Human Breast,” Journal of Pathology, Vol. 211, 2007, pp. 499-506. doi:10.1002/path.2130
[7] G. P. Skliris, P. J. Carder, M. R. Lansdown and V. Speirs, “Immunohistochemical Detection of ERbeta in Breast Cancer: Towards More Detailed Receptor Profiling?” British Journal of Cancer, Vol. 84, No. 5, 2001, pp. 1095-1098. doi:10.1054/bjoc.2001.1721
[8] R. Cullen, T. M. Maguire, E. W. McDermott, A. D. K. Hill, N. J. O. Higgins and M. J. Duffy, “Studies on Oestrogen Receptor-a and -b mRNA in Breast Cancer,” European Journal of Cancer, Vol. 37, No. 9, 2001, pp. 1118-1122.
[9] G. C. Markey, R. Cullen, P. Diggin, A. D. Hill, E. W. Mc Dermott, N. J. O’Higgins and M. J. Duffy, “Estrogen Receptor-Beta mRNA Is Associated with Adverse Outcome in Patients with Breast Cancer,” Tumor Biology, Vol. 30, No. 4, 2009, pp. 171-175. doi:10.1159/000236409
[10] J. Matthews and J. A. Gustafsson, “Estrogen Signaling: A Subtle Balance between ER Alpha and ER Beta,” Molecular Interventions, Vol. 3, No. 5, 2003, pp. 281-292. doi:10.1124/mi.3.5.281
[11] C. P. de, C. Tran-Perennou, C. Elie, E. Boudou, C. Barbaroux, M. F. Poupon, R. Y. De, B. Asselain and H. Magdelenat, “Quantitation of Estradiol Receptors Alpha and Beta and Progesterone Receptors in Human Breast Tumors by Real-Time Reverse Transcription-Polymerase Chain Reaction,” Biochemical Pharmacology, Vol. 64, No. 3, 2002, pp. 507-515.
[12] I. Bieche, B. Parfait, S. Tozlu, R. Lidereau and M. Vidaud, “Quantitation of Androgen Receptor Gene Expression in Sporadic Breast Ttumors by Real-Time RT-PCR: Evidence that MYC Is an AR-Regulated Gene,” Carcinogenesis, Vol. 22, No. 9, 2001, pp. 1521-1526. doi:10.1093/carcin/22.9.1521
[13] L. O. Gonzalez, M. D. Corte, J. Vazquez, S. Junquera, R. Sanchez, A. C. Alvarez, J. C. Rodriguez, M. L. Lamelas and F. J. Vizoso, “Androgen Receptor Expresion in Breast Cancer: Relationship with Clinicopathological Characteristics of the Tumors, Prognosis, and Expression of Metalloproteases and Their Inhibitors,” BMC Cancer, Vol. 8, 2008, p. 149. doi:10.1186/1471-2407-8-149
[14] J. M. Holly and C. M. Perks, “Cancer as an Endocrine Problem,” Best Practice and Research Clinical Endocrinology and Metabolism, Vol. 22, No. 4, 2008, pp. 539-550. doi:10.1016/j.beem.2008.07.007
[15] W. K. Hou, Y. X. Xu, T. Yu, L. Zhang, W. W. Zhang, C. L. Fu, Y. Sun, Q. Wu and L. Chen, “Adipocytokines and Breast Cancer Risk,” Chinese Medical Journal, Vol. 120, No. 18, 2007, pp. 1592-1596.
[16] M. Rahmati-Yamchi, N. Zarghami, M. Rahbani and A. Montazeri, “Plasma Leptin, hTERT Gene Expression, and Anthropometric Measures in Obese and Non-Obese Women with Breast Cancer,” Breast Cancer, Vol. 5, 2011, pp. 27-35.
[17] M. Artac and K. Altundag, “Leptin and Breast Cancer: An Overview,” Medical Oncology, 2011, pp. 1-8. doi:10.1007/s12032-011-0056-0
[18] G. H. Pfeiler, C. Buechler, M. Neumeier, A. Schaffler, G. Schmitz, O. Ortmann and O. Treeck, “Adiponectin Effects on Human Breast Cancer Cells Are Dependent on 17-Beta Estradiol,” Oncology Reports, Vol. 19, No. 11, 2008, pp. 787-793.
[19] I. Kelesidis, T. Kelesidis and C. S. Mantzoros, “Adiponectin and Cancer: A Systematic Review,” British Journal of Cancer, Vol. 94, 2006, No. 9, pp. 1221-1225. doi:10.1038/sj.bjc.6603051
[20] Y. J. Jeong, J. G. Bong, S. H. Park, J. H. Choi and H. K. Oh, “Expression of Leptin, Leptin Receptor, Adiponectin, and Adiponectin Receptor in Ductal Carcinoma in Situ and Invasive Breast Cancer,” Journal of Breast Cancer, Vol. 14, No. 2, 2011, pp. 96-103. doi:10.4048/jbc.2011.14.2.96
[21] B. Sonmez, M. Seker, A. Bilici, E. F. Yavuz, B. B. Oven Ustaalioglu, M. Gumus, G. D. Ozturk, M. Karaduman, C. Gezen, M. Eser, N. Bildik and T. Salepci, “Is There Any Correlation among Adiponectin Levels in Serum, Tumor Tissue and Normal Tissue of the Same Patients with Breast Cancer?” Journal of Balkan Union of Oncology, Vol. 16, 2011, pp. 227-232.
[22] J. P. Bastard, M. Maachi, C. Lagathu, M. J. Kim, M. Caron, H. Vidal, J. Capeau and B. Feve, “Recent Advances in the Relationship between Obesity, Inflammation, and Insulin Resistance,” European Cytokine Network, Vol. 17, No. 1, 2006, pp. 4-12.
[23] J. N. Fain, “Release of Interleukins and Other Inflammatory Cytokines by Human Adipose Tissue is Enhanced in Obesity and Primarily due to the Nonfat Cells,” Journal of Vitamins and Hormones, Vol. 74, No. 6, 2006, pp. 443-477.doi:10.1016/S0083-6729(06)74018-3
[24] O. Treeck, C. Lattrich, I. Juhasz-Boess, S. Buchholz, G. Pfeiler and O. Ortmann, “Adiponectin Differentially Affects Gene Expression in Human Mammary Epithelial and Breast Cancer Cells,” British Journal of Cancer, Vol. 99, No. 8, 2008, pp. 1246-1250. doi:10.1038/sj.bjc.6604692
[25] R. Jahanban-Esfahlan, N. Zarghami, A. Jahanban-Esfahlan, M. Mollazadeh, K. Nejati and M. Nasiri, “The Possible Impact of Obesity on Androgen, Progesterone and Estrogen Receptors (ERα and ERβ) Gene Expression in Breast Cancer Patients,” Breast Cancer: Basic and Clinical Research, Vol. 5, 2011, pp. 227-237. doi:10.4137/BCBCR.S7707
[26] A. R. Carmichael, “Obesity and Prognosis of Breast Cancer,” Obesity Research, Vol. 7, No. 4, 2006, pp. 333-340. doi:10.1111/j.1467-789X.2006.00261.x
[27] J. H. Kang, B. Y. Yu and D. S. Youn, “Relationship of Serum Adiponectin and Resistin Levels with Breast Cancer Risk,” Journal of Korean Medical Science, Vol. 22, No. 1, 2007, pp. 117-121. doi:10.3346/jkms.2007.22.1.117
[28] D. Giuffrida, L. Lupo, G. A. La Porta, G. L. La Rosa, G. Padova, E. Foti, V. Marchese and A. Belfiore, “Relation between Steroid Receptor Status and Body Weight in Breast Cancer Patients,” European Journal of Cancer, Vol. 28, No. 1, 1992, pp. 112-115. doi:10.1016/0959-8049(92)90397-K
[29] C. Zhao, K. Hlman-Wright and J. A. Gustafsson, “Estrogen Receptor Beta: An Overview and Update,” Nuclear Receptor Signaling, Vol. 6, 2008, p. e003.
[30] M. W. Pfaffl, I. G. Lange, A. Daxenberger and H. H. Meyer, “Tissue-Specific Expression Pattern of Estrogen Receptors (ER): Quantification of ER Alpha and ER Beta mRNA with Real-Time RT-PCR,” Acta Pathologica, Microbiologica et Immunologica Scandinavica, Vol. 109, 2001, pp. 345-355. doi:10.1034/j.1600-0463.2001.090503.x
[31] I. Bieche, B. Parfait, I. Laurendeau, I. Girault, M. Vidaud and R. Lidereau, “Quantification of Estrogen Receptor Alpha and Beta Expression in Sporadic Breast Cancer,” Oncogene, Vol. 20, No. 56, 2001, pp. 8109-8115. doi:10.1038/sj.onc.1204917

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.